Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer
Authors:
- 1 March 1981
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 1 (1) , 59-68
Abstract
Eighty-eight postmenopausal women with metastatic breast cancer, in whom estrogen receptors (ER) were positive or unknown, were treated on a controlled trial to determine the effectiveness of tamoxifen and to assess the therapeutic advantage of sequentially adding low-dose cyclophosphamide-methotrexate-5-fluorouracil (CMF) chemotherapy in tamoxifen responders. Patients with known ER negative status were not studied. After the initial 12-week treatment with tamoxifen alone, 60% of ER positive patients achieved complete or partial response as did 35% in whom ER were unknown. Response status further improved in 18% randomized to continue tamoxifen alone vs 31% in whom CMF was added to tamoxifen. There were no statistically significant differences in time to the development of progressive disease or survival between the ER positive and ER unknown patients or between the tamoxifen and tamoxifen plus CMF groups. We conclude that inability to determine ER status should not prejudice against the use of tamoxifen in postmenopausal patients with advanced breast cancer. No benefit has been demonstrated from the addition of CMF chemotherapy in tamoxifen responders.Keywords
This publication has 17 references indexed in Scilit:
- Combination therapy of hormone and cytotoxic agents in advanced breast cancerCancer, 1981
- Randomized Clinical Trial of Diethylstilbestrol versus Tamoxifen in Postmenopausal Women with Advanced Breast CancerNew England Journal of Medicine, 1981
- Dose-Response Effect of Adjuvant Chemotherapy in Breast CancerNew England Journal of Medicine, 1981
- Tamoxifen in advanced breast cancerCancer Treatment Reviews, 1978
- SAFETY OF TAMOXIFENThe Lancet, 1978
- 243. Antitumour activity of the antiestrogen ICI 46,474 (Tamoxifen) in the dimethylbenzanthracene (DMBA)—induced rat mammary carcinoma modelJournal of Steroid Biochemistry, 1974
- Estrogen Receptors in Human Breast CancerJournal of Clinical Investigation, 1973
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971
- A generalized Wilcoxon test for comparing arbitrarily singly-censored samplesBiometrika, 1965
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958